| Management target | Revenue FY27 |
|---|
| Revenue growth | 9% sequential growth to ₹196.1 Cr; H1 revenue at ₹376 Cr. |
|---|---|
| Margins | Gross margin rose to 47.5%; guided to stay above 45%. |
| Demand visibility | Strong visibility in Australia and Philippines via long-term OTC supply contracts. |
| Management confidence | Confident; focus shifted from daily operations to long-term strategic integration. |
Growth
H1 revenue hit ₹376 Cr; gross margins expanded to 47.5% due to tighter inventory and R&D integration.
Outlook
Management maintains a hard target of ₹750 Cr revenue for FY27 with margins exceeding 17%.
Risks
Massive 3x jump in depreciation and logistical disruptions in Australia/Middle East pose immediate earnings volatility risks.
Last quarter's promises, checked
Delivered
- 45:55 H1:H2 split of ₹750 Cr (implied H1 ≈₹337.5 Cr) → H1 ₹376 Cr (= BEAT)
Partly delivered
- ₹18.02 Cr greenfield R&D centre (IPO objective) → ₹15 Cr for 60% of Prathyak; purpose retained (= PARTIAL)
Missed
- ₹83.83 Cr Unit-1/2 upgrade (IPO objective) → dropped; redeployed to 60% of Saicriti greenfield (= MISS)
Earnings Call Transcript filed with NSE, NSE: SAIPARENT. Summary written with AI assistance from the document.
Sai Parenterals Ltd: key numbers
- Share price
- ₹480.70
- Market cap
- ₹2,124 Cr
- Revenue (annual)
- ₹381.0 Cr
- Net profit (annual)
- ₹14.26 Cr
- P/E (TTM)
- 85.2×Sector 47.2×
- Promoter holding
- 51.16%+0.00% QoQ
- FII holding
- 2.85%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Sai Parenterals Ltd
All →Sai Parenterals Other Announcement
Sai Parenterals filed its quarterly shareholding pattern for the quarter ended 30 September 2026. Promoters and promoter group hold 51.16 per cent.
Sai Parenterals Investor Presentation: Key Takeaways
Q2/H1 FY27 deck (Sep 2026) gives no quarterly P&L figures. Highlights: 302 products, 599 registrations, FY26 export share 63%, Saicriti injectable and Noumed acquisitions.
Sai Parenterals Results Update
Sai Parenterals reported Q2FY27 consolidated revenue of Rs. 196 crore and PAT of Rs. 11 crore. Gross margin improved to 47.5%.
Sai Parenterals Acquisition
Sai Parenterals will acquire the remaining 25% stake in its 75% subsidiary SP Analytics for cash, making it wholly owned. Related-party approval was taken at the 1 November 2026 board meeting, with completion by 31 December 2026.
- Execution
- 31-12-2026
Sai Parenterals Q2 FY27 Results: Net Profit ₹10.5 Cr, Up 66.7% YoY
Sai Parenterals Ltd reported revenue from operations of ₹194.9 Cr (+264.3% YoY) and net profit of ₹10.5 Cr (+66.7% YoY) for Q2 FY27.
- Key figure
- Net profit ₹10.5 Cr · +66.7% YoY
Sai Parenterals Board Meeting Date
Sai Parenterals Ltd notified a Board Meeting on 1 Nov 2026 to approve unaudited Q2/H1 FY27 results. No financial figures or decisions are reported yet.